Compare Lowe`s Companies Inc (LOW) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Moderna, Inc. — how do they compare? Lowe`s Companies Inc trades at $186.7 (market cap $105.96B), while Moderna, Inc. trades at $224.91 (market cap $78.65B). The key difference: Lowe`s Companies Inc is the larger of the two by market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Moderna, Inc. for 59 Days on average.
| LOW | MRNA | |
|---|---|---|
Market Cap | $105.96B | $78.65B |
Volume | 4,039,547 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $203.46 |
52-Week Low | $179.50 | $22.36 |
Typical Hold Time | 98 Days | 59 Days |
Enterprise Value | $144.81B | $74.80B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $186.00, up 2.46% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector faces macroeconomic headwinds.
Wall Street maintains a bullish consensus with a $244.09 price target (31 Buy, 19 Hold, 1 Sell), representing 31% upside potential. Key risks include housing market stagnation and competitive pressure from Home Depot. The negative shareholder equity position requires monitoring, but consistent dividend payments and operational cash flow strength provide stability.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
